Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
200
resultados
Última actualización
17/04/2026 [06:54:00]
Resultados 175 a 200 de 200
Resumen de: WO2026072616A1
The present disclosure relates to lipid nanoparticle (LNP) compositions including at least one ionizable cationic lipid and Polyinosinic:polycytidylic acid (poly(I:C)), and compositions and formulations incorporating such LNP compositions. The disclosure also provides methods of using these compositions to elicit an immune response, including for the prevention or treatment of infectious diseases.
Resumen de: WO2026072290A1
Variants of the ZF5.3 peptide having Cys substitutions of one or both His residues of the Cys2His2 Zn(II) coordination site, to form Cys3His (CCHC) or Cys4 (AV5.3), respectively, are used in fusions of the peptides with cargo domains, delivery vehicles and delivery methods.
Resumen de: WO2026071602A1
The present invention relates to: a lipid nanoparticle (LNP) composition for producing NK cells or T cells transformed with CAR, wherein the LNP composition for transforming natural killer (NK) cells or T cells is characterized by comprising a nucleic acid and a novel ionizable lipid; CAR-NK cells and CAR-T cells transformed thereby; and uses thereof. According to the present invention, mRNA can be stably delivered into immune cells through the LNP composition, and the transformed NK cells and T cells exhibit high viability and can highly express the target protein CAR.
Resumen de: WO2026071610A1
The present invention relates to a composition in which a selective organ targeting lipid (SORT lipid) is added to lipid nanoparticles (LNP), which can accurately deliver therapeutic molecules to specific tissues, particularly the spleen or immune cells. The composition exhibits excellent delivery efficiency and in vivo stability, and thus can be advantageously applied in the technical field related to nucleic acid therapeutic agents.
Resumen de: WO2026071633A1
The present invention relates to an inhalable tumor-microenvironment-targeted drug delivery system for treating lung cancer. Specifically, the present invention provides a lipid-polymer hybrid nanoparticle comprising: a poly(lactic-co-glycolic acid) (PLGA) polymer core that encapsulates a first therapeutic agent such as paclitaxel (PTX); and a lipid shell functionalized with pemetrexed (PEM) that performs a dual function as both an anticancer agent and a target ligand. The nanoparticles are directly delivered to the lungs through inhalation, simultaneously target folate receptor alpha (FR-α) of lung cancer cells and folate receptor beta (FR-β) of immunosuppressive tumor-associated macrophages (M2-TAMs) through a PEM ligand, and can repolarize M2-TAMs into an immunoactive M1 phenotype, while exhibiting a direct cancer cell killing effect by PTX and PEM.
Resumen de: WO2026072393A1
A formulation is provided for a spray dried lipid nanoparticle matrix particles, including lipid nanoparticles, a buffer system, and a barrier matrix stabilizer, wherein the barrier matrix stabilizer is included in a solid weight percent based on a maximum osmolarity and a maximum acceptable injectable volume of an injectable formulation comprising the spray dried lipid nanoparticle matrix particles.
Resumen de: WO2026069177A1
A non-infectious bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.
Resumen de: US20260092293A1
This application relates to an engineered RNA molecule, a DNA molecule encoding the engineered RNA molecule, and use of the engineered RNA molecule. The engineered RNA molecule comprises a Poly(A) tail sequence containing an miRNA binding site. The Poly(A) tail enables the accurate expression of a target gene in an organ, a tissue and/or a cell.
Resumen de: WO2026065739A1
Disclosed in the present invention is a short peptide composition for inhibiting inclusion body formation and promoting Gag-Like protein nanoparticle self-assembly, comprising a C-terminus short peptide and an N-terminus short peptide. The amino acid sequence of the N-terminus short peptide is as shown in SEQ ID NO: 1, and the amino acid sequence of the C-terminus short peptide is as shown in SEQ ID NO: 2. The short peptide composition can effectively avoid the formation of an inclusion body of a prokaryotically expressed protein and/or promote the solubilization of the prokaryotically expressed protein. Furthermore, by binding the composition to HIV-1 p24 and human endogenous retrovirus K capsid protein CA, nanoparticles are respectively prepared, which can be used as carriers for antigen surface display or drug delivery. Nanoparticles formed from HIV-1 capsid protein p24 and human HERV K CA both have cavities significantly larger than those of ferritin, leading to a greater loading capacity, and also exhibit good stability and wide applicability as antigen display platforms.
Resumen de: AU2024344058A1
Disclosed are lipidoid compounds having the structure of formula (X) or formula (I): wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.
Resumen de: AU2024330157A1
Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least an ionizable lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the ionizable lipid fraction comprises at least one ionizable glycerol dialkyl glycerol tetraether (GDGT) lipid. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine. In a further aspect, the invention relates to the ionizable GDGT lipids and methods for producing them.
Resumen de: AU2024328597A1
In some aspects, the present disclosure provides methods for generating CAR T cells in situ. The present disclosure provides lipid nanoparticles that selectively target a spleen cell, in particular, a lymphocyte such as a T cell. The lipid nanoparticle provided herein contain a five component composition that includes a permanently anionic lipid giving the lipid nanoparticle an apparent pKa of less than 6.
Resumen de: US20260090989A1
The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
Resumen de: US20260091104A1
The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
Resumen de: US20260090991A1
Disclosed are pharmaceutical compositions containing micronized antibodies encapsulated and/or dispersed in polymeric particles for antibody delivery. The judicious identification of (i) a subset of polymers, (ii) polymers with certain average molecular weights, (iii) a subset of antibody loadings, and/or (iv) pre-loading antibody processing, leads to formation of polymeric particles that possess minimal to no initial burst release of micronized antibody at zero time point. The pharmaceutical compositions are formulated for oral, subcutaneous, or percutaneous administration, and are particularly suited for treatment regimens that involve antibody-based therapy.
Resumen de: US20260091126A1
Described herein is the preparation and use of amino acid-modified lipids for delivery of a small interfering RNA (siRNA), mRNA, miRNA, shRNA, or oligonucleotide via formation of lipid nanoparticles (LNPs) comprising the siRNA, mRNA, miRNA, shRNA, or oligonucleotide and the amino acid-modified lipid. Use of the described lipid nanoparticles to silence overexpression of oncogenes is described.
Resumen de: US20260090997A1
This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.
Resumen de: US20260091128A1
In one aspect, a block copolymer described herein comprises a hydrophilic block including oxazoline monomer or oxazine monomer, and a cationic block comprising monomer including a linear or branched polyamine side chain. In another aspect, a polyion complex comprises a block copolymer comprising a hydrophilic block including oxazoline monomer or oxazine monomer, and a cationic block comprising monomer including a linear or branched cationic polyamine side chain, and a negatively charged biomolecular species associated with the block copolymer. The negatively charged biomolecular species can comprise one or more nucleic acids, such as RNA, DNA, and/or other oligonucleotides.
Resumen de: US20260091129A1
Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of the pathogenic protein is provided, which comprises a nanocarrier and a protein-targeting binding peptide grafted on the nanocarrier. The nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; on the other hand, the use of the nanocomposite in the preparation of drugs including an anti-tumor nanodrug and a Huntington's disease inhibiting drug is provided. The nanocomposite can simulate a key receptor protein in a selective autophagy pathway, so that the pathogenic protein to be degraded can be brought into an autophagosome to be degraded by means of an autophagy pathway, thereby effectively solving the problem that PROTACs cannot degrade large-molecular-weight protein aggregates and LYTACs cannot degrade cytoplasmic proteins.
Resumen de: US20260091125A1
The invention provides multifunctional system for the synchronized delivery of distinct immunoglobulins, in particular antibodies and antibody fragments to specific cancerous cells and tissues located outside of the brain. The multifunctional system is based on an inorganic core particle which is conjugated through a first polymeric linker to a first immunoglobulin; through a second polymeric linker to a second immunoglobulin; through a third polymeric linker to a penetration enhancing moiety; and to a fourth, monofunctional capping linker or spacer. Further provided are a process for preparation of the multifunctional system, pharmaceutical compositions comprising the multifunctional system and uses thereof in therapeutic and/or diagnostic methods.
Resumen de: US20260091107A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.
Resumen de: US20260090957A1
The invention relates to processes for making pharmaceutical aqueous therapeutic particles (AQTP) having stable exterior water clustering with nanosized thickness between 1 to 300 nanometers wherein the AQTP has increased bioavailability when administered to a mammal compared to conventional pharmaceutical drug particles administered to the mammal. The invention relates to an improved process apparatus which is computer controlled, capable of continuous operation with high efficiency so as to make a more consistently acceptable AQTP compared to an previous prototype process apparatus of the Inventors. The invention provides compositions comprising of AQTP which comprise a substance selected from the group consisting of a cannabinoid such as CBD, a cell membrane pore-forming peptide such as PNC-27, a psychoactive drug, a pharmaceutical, a nutraceutical, a mineral, an anion, a cation, a protein, a peptide, an amino acid, a polymer, a vitamin, an antioxidant, a fertilizer, a chemical, a medical use product, a medical kit use product, a personal consumer use product, a manufacturing use product, an energy use product such as a battery, and any combination thereof.
Resumen de: AU2026201855A1
Provided is a polymer comprising a hydrolysable polymer backbone, the polymer backbone comprising (i) monomer units with a side chain comprising a hydrophobic group; (ii) monomer units with a side chain comprising an oligoamine or polyamine; and optionally (iii) monomer units with a side chain comprising an ionizable group, as well as a method of preparing said polymer, and a method of delivering a nucleic acid and/or polypeptide to a cell using the polymer. ar a r
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Nº publicación: WO2026069376A1 02/04/2026
Solicitante:
PULSE PHARMACEUTICALS PVT LTD [IN]
PULSE PHARMACEUTICALS PVT LTD
Resumen de: WO2026069376A1
The present invention provides a topical aqueous nano-dispersion composition comprising at least one antifungal agent and lipid carrier particles, wherein the at least one antifungal agent is entrapped within the lipid carrier particles in molecular form. The nano-dispersion has drug entrapment efficiency in the range of 70 to 97%. The present invention further provides process of preparing the composition, method of treating/preventing a fungal infection and use thereof.
BOPI
Sede Electrónica
